Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021
Grünwald, February 12, 2021 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of off-patent branded pharmaceuticals for selected therapeutic areas, expects the collaboration with BioNTech SE, Mainz, Germany, for the production of the Covid-19 vaccine Comirnaty® to contribute a high double-digit million € amount to the consolidated sales of the Dermapharm Group in the full year 2021. This is the result of a current plan for vaccine production approved by the Dermapharm Management Board today. Among other things, it includes the establishment of additional production capacities at the Reinbek site, which are scheduled to go into operation in May 2021.
In September 2020, Dermapharm signed a cooperation and supply agreement with BioNTech SE to support the production of the vaccine Comirnaty®. At the main production site at mibe GmbH Arzneimittel in Brehna, Dermapharm has expanded production and special storage capacities for the formulation as well as the aseptic filling, packaging (fill & finish) and storage of the vaccine. The vaccine has been produced in Brehna since the beginning of October 2020.
Due to the high demand for the vaccine, additional production capacities are now being established at Allergopharma GmbH & Co. KG, a subsidiary of Dermapharm, at the Reinbek site. Initial personnel are already being recruited and employees are being trained in Brehna in order to be able to start vaccine production as soon as possible.
“At Allergopharma, we have the necessary prerequisites and also the internal know-how to set up vaccine production at short notice. We will build up capacities in Reinbek that significantly exceed our production capacities in Brehna. We owe the short-term implementation in particular to the constructive cooperation with BioNTech, our suppliers and employees, and the responsible authorities,” continues Dr. Feldmeier. “We are very proud and highly motivated to be able to make an important contribution to combating the pandemic with this partnership. Our high flexibility for the cooperation with BioNTech proves once again the necessity to maintain production capacities for pharmaceuticals at the location Germany / Europe.”
Dermapharm – Pharmaceutical Excellence “Made in Germany”
Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a trained medical and pharmaceutical sales force. Dermapharm has more than 380 active pharmaceutical ingredients for more than 1,300 marketing authorisations (Arzneimittelzulassungen), which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This range makes the company unique. Besides Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business that operates under the “axicorp” brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2019. In the “Herbal extracts” segment, Dermapharm has access to the growth market for herbal pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of herbal extracts and natural active ingredients.
With a consistent R&D strategy and numerous successful product and company acquisitions over the past 30 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.
Investor Relations &
Phone: +49 (0)89 – 64186-233
Fax: +49 (0)89 – 64186-165
Phone: +49 (0)611 – 205855-28
Fax: +49 (0)611 – 205855-66